Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ACE | P12821 | 6/20 | 0.44 |
| ▸ | REN | P00797 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PEPD | P12955 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3711047 | 1.00 | CNR1 (0.47) | CNR1CNR2RAB9ASMN1; SMN2ACE | |
| SCHEMBL3138576 | 0.95 | RAB9A (0.51) | CNR1CNR2RAB9AACEREN | |
| SCHEMBL1955445 | 0.95 | RAB9A (0.51) | CNR1CNR2RAB9AACEREN | |
| SCHEMBL3138588 | 0.95 | RAB9A (0.51) | CNR1CNR2RAB9AACEREN | |
| SCHEMBL5701940 | 0.87 | RAB9A (0.42) | CNR1CNR2RAB9AACEREN | |
| SCHEMBL11543098 | 0.87 | RAB9A (0.42) | CNR1CNR2RAB9AACEREN | |
| SCHEMBL5702070 | 0.87 | RAB9A (0.42) | CNR1CNR2RAB9AACEREN | |
| SCHEMBL25664005 | 0.86 | CNR1 (0.50) | CNR1CNR2RAB9ASMN1; SMN2ACE | |
| SCHEMBL25664006 | 0.86 | CNR1 (0.50) | CNR1CNR2RAB9ASMN1; SMN2ACE | |
| SCHEMBL4597804 | 0.84 | CNR1 (0.46) | CNR1CNR2RAB9ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398771-A2 | HETEROCYCLIC COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2011-12-28 | — | — | EP | claimed |
| WO-2010096371-A2 | HETEROCYCLIC COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-08-26 | — | — | WO | claimed |
| US-11578054-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-02-14 | — | — | US | disclosed |
| US-20210387941-A1 | Diphenyl-like Compound, Intermediate Thereof, Preparation Method Therefor, Pharmaceutical Composition Thereof And Uses Thereof | SHANGHAI MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2021-12-16 | — | — | US | disclosed |
| US-20210094932-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2021-04-01 | — | — | US | disclosed |
| US-8889670-B2 | Heterocyclic compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-7109215-B2 | Compounds possessing neuronal activity | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-09-19 | — | — | US | disclosed |
| US-20020013351-A1 | Compounds possessing neuronal activity | VERTEX PHARMACEUTICALS INCORPORATED | 2002-01-31 | — | — | US | disclosed |
| US-6268384-B1 | DO NOT BIND TO FKBP, AND WHICH DO NOT HAVE MULTI-DRUG RESISTANCE REVERSAL ACTIVITY. | VERTEX PHARMACEUTICALS INCORPORATED | 2001-07-31 | — | — | US | disclosed |
| CN-1271354-A | Compounds possessing neuronal activity | VERTEX PHARMA (US) | 2000-10-25 | — | — | CN | disclosed |
| EP-1007521-A1 | COMPOUNDS POSSESSING NEURONAL ACTIVITY | Vertex Pharmaceuticals Incorporated (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999010340-A1 | COMPOUNDS POSSESSING NEURONAL ACTIVITY | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094932-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | CD74, HLA-DRB1, CD47 | CNR1 2640/4885CNR2 2213/4885RAB9A 1942/4885 |
| US-11578054-B2 | Compounds useful as immunomodulators | CD74, HLA-DRB1, CD47 | CNR1 2640/4885CNR2 2213/4885RAB9A 1942/4885 |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CNR1 2/4885CNR2 1/4885RAB9A 2445/4885 |
| US-20020013351-A1 | Compounds possessing neuronal activity | BDNF, NGF, GAP43 | CNR1 1539/4885CNR2 1776/4885RAB9A 1272/4885 |
| US-20210387941-A1 | Diphenyl-like Compound, Intermediate Thereof, Preparation Method Therefor, Pharmaceutical Composition Thereof And Uses Thereof | CD274, PDCD1LG2, PDCD1 | CNR1 2667/4885CNR2 3368/4885RAB9A 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.